Steven M Frank1, Robert A Sikorski2, Gerhardt Konig3, Diamantis I Tsilimigras4, Jan Hartmann5, Mark A Popovsky5, Timothy M Pawlik6, Jonathan H Waters3. 1. Johns Hopkins Health System Blood Management Program, Armstrong Institute for Patient Safety and Quality, Department of Anesthesiology/Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. 2. Department of Anesthesiology/Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. 3. Department of Anesthesiology & Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Surgery, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. 5. Haemonetics Corporation, Braintree, MA, USA. 6. Department of Surgery, The Ohio State University Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, USA. tim.pawlik@osumc.edu.
Abstract
INTRODUCTION: Autologous salvaged blood, commonly referred to as "cell saver" or "cell salvage" blood, is an important method of blood conservation. Understanding the mechanism of action and summarizing the existing evidence regarding the safety, efficiency, and the relative costs of cell salvage may help educate clinicians on how and when to best utilize autotransfusion. METHODS: This review focuses on issues concerning the quality of red blood cells (RBC), efficiency, and the cost effectiveness relative to autotransfusion. The key considerations of safe use and clinical applicability are described along with the challenges for wider dissemination. RESULTS: Cell salvage can reduce requirements for allogeneic transfusions, along with the associated risks and costs. Autologous salvaged RBCs provide high-quality transfusion, since the cells have not been subjected to the adverse effects of storage as occurs with banked blood. The risks for RBC alloimmunization and transfusion-related infectious diseases are also avoided. With a careful selection of cases, salvaged blood can be more cost effective than donor blood. Cell salvage may have a role in cardiac, major vascular, orthopedic, transplant, and trauma surgeries. However, there remain theoretical safety concerns in cases with bacterial contamination or in cancer surgery. CONCLUSION: In addition to other methods of blood conservation used in patient blood management programs, autologous salvaged blood adds value and is cost effective for appropriate surgical cases. Evidence suggests that autologous salvaged blood may be of higher quality and confer a cost reduction compared with the allogeneic banked blood, when used appropriately.
INTRODUCTION: Autologous salvaged blood, commonly referred to as "cell saver" or "cell salvage" blood, is an important method of blood conservation. Understanding the mechanism of action and summarizing the existing evidence regarding the safety, efficiency, and the relative costs of cell salvage may help educate clinicians on how and when to best utilize autotransfusion. METHODS: This review focuses on issues concerning the quality of red blood cells (RBC), efficiency, and the cost effectiveness relative to autotransfusion. The key considerations of safe use and clinical applicability are described along with the challenges for wider dissemination. RESULTS: Cell salvage can reduce requirements for allogeneic transfusions, along with the associated risks and costs. Autologous salvaged RBCs provide high-quality transfusion, since the cells have not been subjected to the adverse effects of storage as occurs with banked blood. The risks for RBC alloimmunization and transfusion-related infectious diseases are also avoided. With a careful selection of cases, salvaged blood can be more cost effective than donor blood. Cell salvage may have a role in cardiac, major vascular, orthopedic, transplant, and trauma surgeries. However, there remain theoretical safety concerns in cases with bacterial contamination or in cancer surgery. CONCLUSION: In addition to other methods of blood conservation used in patient blood management programs, autologous salvaged blood adds value and is cost effective for appropriate surgical cases. Evidence suggests that autologous salvaged blood may be of higher quality and confer a cost reduction compared with the allogeneic banked blood, when used appropriately.
Authors: Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson Journal: Cochrane Database Syst Rev Date: 2010-04-14
Authors: Katherine E Poruk; Vicente Valero; Tyler Saunders; Amanda L Blackford; James F Griffin; Justin Poling; Ralph H Hruban; Robert A Anders; Joseph Herman; Lei Zheng; Zeshaan A Rasheed; Daniel A Laheru; Nita Ahuja; Matthew J Weiss; John L Cameron; Michael Goggins; Christine A Iacobuzio-Donahue; Laura D Wood; Christopher L Wolfgang Journal: Ann Surg Date: 2016-12 Impact factor: 12.969
Authors: Osman N Salaria; Viachaslau M Barodka; Charles W Hogue; Dan E Berkowitz; Paul M Ness; Jack O Wasey; Steven M Frank Journal: Anesth Analg Date: 2014-06 Impact factor: 5.108
Authors: Samuel Abraham Joseph; Ketevan Berekashvili; Marjorie M Mariller; Michael Rivlin; Krishn Sharma; Andrew Casden; Fabian Bitan; Paul Kuflik; Michael Neuwirth Journal: Spine (Phila Pa 1976) Date: 2008-10-01 Impact factor: 3.468
Authors: Steven M Frank; Bagrat Abazyan; Masahiro Ono; Charles W Hogue; David B Cohen; Dan E Berkowitz; Paul M Ness; Viachaslau M Barodka Journal: Anesth Analg Date: 2013-02-28 Impact factor: 5.108
Authors: Andrew V Scott; Enika Nagababu; Daniel J Johnson; Khaled M Kebaish; Joshua A Lipsitz; Ian M Dwyer; Gabriel S Zuckerberg; Viachaslau M Barodka; Dan E Berkowitz; Steven M Frank Journal: Anesth Analg Date: 2016-03 Impact factor: 6.627